| antibiotic resistance | The ability of a bacterium tosynthesise a protein that neutralises an antibiotic. (09 Oct 1997) |
|---|---|
| antibiotic resistance gene | Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it. (09 Oct 1997) |
| antibiotic sensitivity | Microbial susceptibility to antibiotics. See: antibiotic sensitivity test, minimal inhibitory concentration. (05 Mar 2000) |
| antibiotic sensitivity test | The in vitro testing of bacterial cultures with antibiotics to determine susceptibility of bacteria to antibiotic therapy. (05 Mar 2000) |
| antibiotic-resistant | Indicating microorganisms that continue to multiply although exposed to antibiotic agents. (05 Mar 2000) |
| antibiotics | Drugs that fight infections. (12 Dec 1998) |
| antibiotics, aminoglycoside | Antibiotics whose structure contains amino sugars attached to an aminocyclitol ring (hexose nucleus) by glycosidic bonds. Aminoglycoside antibiotics are derived from various species of streptomyces and micromonospora or are produced synthetically. They act by inhibiting protein synthesis. (12 Dec 1998) |
| antibiotics, anthracycline | Antibiotics which have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to a sugar molecule. These antibiotics have potent antineoplastic activity. The two best known members of this group are daunorubicin and doxorubicin. Since these agents intercalate with DNA, many DNA functions are adversely affected. Futhermore they interact with cell membranes thereby altering their functions and also generate hydrogen peroxide and hydroxy radicals which are highly destructive to cells. (12 Dec 1998) |
| antibiotics, antifungal | Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases. (12 Dec 1998) |
| antibiotics, antineoplastic | Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms. (12 Dec 1998) |
| antibiotics, antitubercular | Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. (12 Dec 1998) |
| antibiotics, combined | Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antibiotics, glycopeptide | Antibiotics whose structure contains one or more cyclic peptides to which are attached one or more deoxy sugars in glycosidic linkage. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| antibiotics, lactam | Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins; their analogs and derivatives, such as the penem (or penam) compounds; clavulanic acids; and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases. (12 Dec 1998) |
| antibiotics, macrolide | A group of antibiotics containing a macrocyclic lactone ring linked glycosidically to one or more sugar moieties. These antibiotics are produced by certain species of streptomyces. They often inhibit protein synthesis by binding to the 50s subunits of 70s ribosomes. (12 Dec 1998) |